Breast Surgery
Conditions
Keywords
Breast, Surgery, anaesthetics
Brief summary
The block (ESP or PVB) will be performed preoperatively in the recovery room under standard monitoring. After setting a peripheral venous access, patient will be installed on lateral decubitus position on the opposite side of the block.
Detailed description
The block will be performed with IV Remifentanil sedation Target-Controlled Infusion mode at 2ng/ml and oxygen therapy. For the erector spinae plane block: The puncture will be performed with ultrasound guidance. The ultrasound probe will be placed parallel to the spine parasagittally at the T3 transverse process level. The needle will be introduced and visualized to the plane of the ultrasound image (in plane). The desired injection site is between the fascia of the erector muscle of the spine and the transverse process at the T3 level. The operator ensures the correct localization of the needle with saline solution. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml. For paravertebral block: The T2 intervertebral space will be located by identifying compared to C7, a prominent cervical vertebra, or by ultrasound by counting the thoracic vertebrae from the first rib. The paravertebral space will be identified by placing the ultrasound probe in a parasagittal or transverse position. The needle will go through the paravertebral muscles and the costo-transverse ligament or by a latero-medial approach using ultrasound. The block will be performed using a 22-gauge 8cm long needle. When the paravertebral space has been reach, an aspiration test will be performed and then 0.6 ml/kg of solution (Ropivacaine hydrochloride solution at 5 mg/ml up to 30 ml) will be injected.
Interventions
DRUGRopivacaïne Hydrochloride by Erector Spinae block
Ropivacaïne Hydrochloride Erector Spinae puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
DRUGRopivacaïne Hydrochloride by Paravertebral block
Paravertebral puncture will be performed with ultrasound guidance. Then 0.50% Ropivacaine hydrochloride will be injected at a dose of 0.6 ml/kg of actual weight, without exceeding 30 ml.
Sponsors
National Cancer Institute, France
Institut Curie
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
A Double-blind Randomized non-inferiority Trial of erector spinae block (ESP) versus paravertebral block (PVB)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Woman with breast adenocarcinoma without metastasis or breast in situ adenocarcinoma (with or without breast reconstruction by prosthesis) to by treated: * either by breast-conserving surgery with axillary dissection, * either by modified radical mastectomy with axillary dissection * either by modified radical mastectomy with lymph node dissection * either by modified radical mastectomy without axillary 2. Patients aged between 18 and 85 years old. 3. ASA class 1, 2 or 3 (Physical Status Classification System of American Society of Anesthesiologists (ASA)). 4. Signed informed consent form. 5. Patient able to answer self-assessment questionnaires (sufficient understanding of evaluations and in French). 6. Patient affiliated to the health care insurance.
Exclusion criteria
1. Preoperative consumption of opioid in the patient's current medications within three months before inclusion. 2. Ipsilateral breast surgery during 3 months prior to the inclusion. 3. Allergy to local anaesthetics and morphine and NSAID. 4. Local skin inflammation at the puncture area. 5. Bilateral breast surgery planned at inclusion. 6. Major immediate ipsilateral breast reconstruction by using tissue flap procedure (example: latissimus dorsi flap, Deep Inferior Epigastric Perforator (DIEP), Transverse Rectus Abdominis Musculocutaneous (TRAM)…). 7. Any contra-indication or patient's refusal for regional anesthesia. 8. Male subjects. 9. Pregnant woman or breastfeeding. 10. B blocker medication. 11. Patient already participating in an analgesia protocol that may interfere with the pain assessment criteria. 12. Patient under legal protection. 13. Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of ESP versus PVB on acute postoperative pain | 24 hours | Percentage of patients needed morphine during the first two postoperative hours in each treatment arm |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Consumption of remifentanil in the Operating Room (OR) | During the period from the surgical incision to the end of the surgical dissection | Dose of Remifentanil during the Operating Room (OR) period |
| Acute early postoperative pain by Visual Analog Scale (VAS) | 24 hours | VAS (no pain=0, worst pain=10) at arrival in the PACU, every 30 minutes in the Post-Anaesthesia Care Unit (PACU), VAS at 4 and 24 hours. Pain scores will be evaluated at rest and after shoulder movement |
| Postoperative morphine consumption | 2 hours | Dose of opioid, in the Post-Anesthesia Care Unit (PACU) |
| Incidence of complications and side effects of each block | 30 days | Complications and side effects of each block will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 5.0) |
| Post-operative extend of dermatomes blocked | 2 hours | The extent of dermatomes blocked as measured by clinical examination to determine area where temperature perception change |
| Percentage of nausea or vomiting | 2 hours | Number of patient who related nausea or vomiting side effects will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 5.0) |
Countries
France
Outcome results
None listed